PQA Opioid Measures and Evaluations

Video

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and what they evaluate during the PQA Annual Meeting in Baltimore, MD.

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and what they evaluate during the PQA Annual Meeting in Baltimore, MD.

Lisa Hines, PharmD: So, our 3 new measures look at opioid prescribing. So, these are new starts, and it looks at long duration greater than 7 day’s supply, or a high dose, or it looks at initial use of long-acting or extended release opioid. And these are for high plans using administrative claims data. So, these prescribing patterns are important, because they’re correlated with increased risk of downstream, chronic opioid use which can contribute to misuse, and even overdose. So, we consider them a really important way at preventing downstream, long-term use.

Related Videos
Young depressed woman talking to lady psychologist during session, mental health - Image credit: motortion | stock.adobe.com
man taking opioid pills sitting at a dark table - Image credit: rohane | stock.adobe.com
schizophrenic man - mental disorder - Image credit: Andreza | stock.adobe.com
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit: Sergey | stock.adobe.com - Unhappy woman with insomnia lying on bed next to alarm clock at night
© 2024 MJH Life Sciences

All rights reserved.